Vaginal Microbiota Transplantation: The Next Frontier
Vaginal Microbiota Transplantation: The Next Frontier
复制标题
DOI：
10.1177/1073110519897731
复制
发表时间：
2019-12-01
影响因子：
2.1
通讯作者：
Ensign, Laura M.
中科院分区：
文献类型：
--
作者：
DeLong, Kevin;Zulfiqar, Fareeha;Ensign, Laura M.
粪便微生物区系移植(FMT)作为治疗艰难梭状芽胞杆菌感染(CDI)的成功，激起了人们对微生物区系移植作为一种治疗多种疾病和条件的潜力的兴奋。在这篇文章中，我们讨论了阴道微生物区系移植(VMT)作为微生物区系移植的“下一个前沿”，并确定了与这一新兴领域相关的医学、法规和伦理挑战。我们进一步讨论了我们预期的将是在临床试验中测试VMT的第一个背景，防止一种被称为细菌性阴道病(BV)的疾病的复发。我们还比较了VMT和FMT的临床方面，并评论了VMT在可能影响研究设计和监管决策的方式上与FMT的相似或不同。
The success of fecal microbiota transplantation (FMT) as a treatment for Clostrioides difficile infection (CDI) has stirred excitement about the potential for microbiota transplantation as a therapy for a wide range of diseases and conditions. In this article, we discuss vaginal microbiota transplantation (VMT) as "the next frontier" in microbiota transplantation and identify the medical, regulatory, and ethical challenges related to this nascent field. We further discuss what we anticipate will be the first context for testing VMT in clinical trials, prevention of the recurrence of a condition referred to as bacterial vaginosis (BV). We also compare clinical aspects of VMT with FMT and comment on how VMT may be similar to or different from FMT in ways that may affect research design and regulatory decisions.